DROST E 200

DESCRIPTION
Drostanolone Enanthate 200 is a synthetic derivative of dihydrotestosterone, producing an anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance in humans. Since it is a derivative of dihydrotestosterone, drostanolone does not aromatize to estrogens. Drostanolone Enanthate 200 has significant anabolic and androgenic properties promoting an increase in Te strength and growth of muscle tissue while acting as an estrogen antagonist. The combination of a short-acting propionate ester with a longacting enanthate ester pro- duces rapid increases in serum drostanolone levels with a Sustained duration of 5-8 days.

INDICATIONS
To rapidly restore muscle tissue atrophied during recovery from a traumatic injury. To offset muscle catabolism in patients with a wasting syndrome.DA To treat certain types of anemia which are non-responsive to first line agents. Oestrogen antagonist in treatment of breast cancer.

CONTRAINDICATIONS
Not indicated for women, children, or the elderly. Women who are pregnant or may become pregnant because of possible masculinization of the fetus. Patients with nephrosis or the nephrotic phase of nephritis. Patients with hypercalcemia. Patients suffering from testicular cancer, prostate cancer, breast cancer, liver damage, kidney damage, stroke, high blood pressure, heart disease or respiratory problems.

ADVERSE REACTIONS
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.
Nervous System: Changes in libido, aggression, headache, anxiety, depression, and generalized paresthesia.
Metabolic: reduced glucose tolerance, increased creatinine clearance, and inhibition of gonadotropin secretion.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea. PATIENT MONITORING Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests – AST/ALT Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal luoR examination and evaluate PSA prior to androgen use. mo Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.

DOSAGE AND ADMINISTRATION
Adult male: 100 – 150 mg injected IM every 3-5 days for a duration of 4-8 weeks.

PRESENTATION
Drostanolone Enanthate 200 mg/ml, 10 ml multiple dose vial.

STORAGE
Store in a cool dry place between 15 -25°C. Protect from light.